Celcuity Inc. (CELC)
NASDAQ:CELC
Want to see CELC full AI Analyst Report?
CELC Stock Chart & Stats
$122.46
-$0.35(-2.63%)
At close: 4:00 PM EST
$122.46
-$0.35(-2.63%)
Day’s Range― - ―
52-Week Range$10.26 - $151.02
Previous CloseN/A
Volume14.25K
Average Volume (3M)1.08M
Market Cap
$6.74B
Enterprise Value$6.79B
Total Cash (Recent Filing)$145.19M
Total Debt (Recent Filing)$195.58M
Price to Earnings (P/E)―
Beta0.40
Next Earnings
Aug 06, 2026EPS Estimate
-1.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.89
Shares Outstanding48,766,290
10 Day Avg. Volume1,057,520
30 Day Avg. Volume1,076,190
Financial Highlights & Ratios
PEG Ratio-0.88
Price to Book (P/B)52.11
Price to Sales (P/S)0.00
P/FCF Ratio-34.13
Enterprise Value/Market Cap1.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-78.06K
Enterprise Value/Ebitda-39.33
Forecast
1Y Price Target
$171.13Price Target Upside39.74% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-3.99
Revenue Forecast (FY)$57.21M
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy And SafetyPivotal trial data showing improved tolerability and a progression-free survival benefit support the drug's clinical profile and increase the likelihood of favorable labeling.
Commercial Readiness And Financial RunwayManagement's disclosure of sufficient cash and short-term investments alongside built commercial infrastructure reduces near-term financing risk and supports potential product launch efforts.
Regulatory ReviewFDA acceptance of the new drug application for gedatolisib and assignment of Priority Review shortens the pathway toward potential approval and market access.
Bears Say
Catalyst Timing And Financing PressureUncertainty about the mutant cohort readout timing combined with high short interest and ongoing cash burn elevates the risk of stock volatility and potential need for additional financing.
Competitive Pressure And Commercial ExecutionCompetition from large pharmaceutical firms with established breast cancer franchises could constrain market share and pricing even if approval is achieved.
Valuation RiskStock appears priced for perfection for a pre-revenue, single-asset company, leaving limited room for upside and greater downside if clinical or regulatory outcomes fall short.
Celcuity News
CELC FAQ
What was Celcuity Inc.’s price range in the past 12 months?
Celcuity Inc. lowest stock price was $10.26 and its highest was $151.02 in the past 12 months.
What is Celcuity Inc.’s market cap?
Celcuity Inc.’s market cap is $6.74B.
When is Celcuity Inc.’s upcoming earnings report date?
Celcuity Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 71 days.
How were Celcuity Inc.’s earnings last quarter?
Celcuity Inc. released its earnings results on May 14, 2026. The company reported -$0.97 earnings per share for the quarter, beating the consensus estimate of -$1.04 by $0.07.
Is Celcuity Inc. overvalued?
According to Wall Street analysts Celcuity Inc.’s price is currently Undervalued.
Does Celcuity Inc. pay dividends?
Celcuity Inc. does not currently pay dividends.
What is Celcuity Inc.’s EPS estimate?
Celcuity Inc.’s EPS estimate is -1.11.
How many shares outstanding does Celcuity Inc. have?
Celcuity Inc. has 48,766,290 shares outstanding.
What happened to Celcuity Inc.’s price movement after its last earnings report?
Celcuity Inc. reported an EPS of -$0.97 in its last earnings report, beating expectations of -$1.04. Following the earnings report the stock price went up 2.197%.
Which hedge fund is a major shareholder of Celcuity Inc.?
Currently, no hedge funds are holding shares in CELC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Celcuity Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$171.13 (39.74% Upside)
$171.13 (39.74% Upside)
Blogger Sentiment
Bullish
CELC Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 42.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.9%
Last 30 Days ▲ 7.8%
Last 30 Days ▲ 7.8%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
1186.01%
12-Months-Change
Fundamentals
Return on Equity
-244.61%
Trailing 12-Months
Asset Growth
88.04%
Trailing 12-Months
Company Description
Celcuity Inc.
Celcuity Inc., a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, and advanced or metastatic breast cancer. The company is also developing CELsignia MP test, a qualitative laboratory developed test that measures HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor cells. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was founded in 2011 and is headquartered in Minneapolis, Minnesota.
CELC Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call was clinically very positive: robust Phase III efficacy signals in both wild-type and mutant cohorts, expansion into first-line studies, promising prostate cancer combo data, IP and formulation work for a subcutaneous version, and a staffed commercial organization targeting a large (~$5B+) second-line market and potential peak revenues up to $2.5B. Offsetting these achievements are materially higher losses and cash burn (net loss up ≈43%, non-GAAP loss up ≈35%, operating cash use up ≈54%), a large increase in SG&A (≈176%), runway that extends through 2027 only with debt drawdowns, and regulatory/clinical timelines (notably first-line data by 2028–2030 and potential additional studies for subcutaneous formulation) that delay broader commercialization. On balance, strong clinical progress and commercial preparations outweigh the near-term financial and timing challenges, but the company will need to manage cash and regulatory requirements closely.View all CELC earnings summariesCELC Stock 12 Month Forecast
Average Price Target
$171.13
▲(39.74% Upside)
Technical Analysis
―
IDEAYA Biosciences
―
Tarsus Pharmaceuticals
―
Belite Bio, Inc. ADR
―
Apogee Therapeutics
―
Ownership Overview
24.35% Insiders
11.80% Mutual Funds
9.67% Other Institutional Investors
44.16% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---